Search Results
Your search for ,itS matches 8760 pages
Showing 8251 - 8300FDA Approves Necitumumab Combination for Metastatic Squamous NSCLC
The U.S. Food and Drug Administration today approved necitumumab (Portrazza) in combination with gemcitabine and cisplatin for first-line treatment of patients with metastatic squamous non–small cell lung cancer (NSCLC). Necitumumab is not indicated for treatment of nonsquamous NSCLC....
FDA Approves Nivolumab to Treat Advanced Kidney Cancer
The U.S. Food and Drug Administration today approved nivolumab (Opdivo) to treat patients with metastatic renal cell carcinoma who have received a prior antiangiogenic therapy. Nivolumab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2,...
Chitosane-Based Injectable Biogel Delivers Anticancer Agents Directly Into Tumors in Laboratory Setting
A new, injectable “biogel” is effective in delivering anticancer agents directly into cancerous tumors and killing them, according to a study published by Monette et al in Biomaterials. The technology was developed by researchers at the University of Montreal Hospital Research Centre...
Study Advances Potential Test to Distinguish Precancerous Pancreatic Cysts From Harmless Ones
In a retrospective analysis of data from 130 patients with pancreatic cysts, scientists at Johns Hopkins have used gene-based tests and a fixed set of clinical criteria to more accurately distinguish precancerous cysts from those less likely to do harm. The findings may eventually help some...
Patients With Breast Cancer Who Have Prescription Drug Benefits, Higher Incomes More Likely to Start and Continue Hormonal Therapy
A University of Colorado Cancer Center study published by Bradley et al in Breast Cancer Research and Treatment showed that patients with breast cancer whose health insurance plans included prescription drug benefits were 10% more likely to start important hormonal therapy than patients who did not ...
Yoga Helps Maintain Quality of Life, May Lessen Side Effects in Men Undergoing Prostate Cancer Treatment
Men with prostate cancer who are undergoing radiation therapy can benefit from yoga, researchers at the Perelman School of Medicine at the University of Pennsylvania reported at the Society for Integrative Oncology’s 12th International Conference. The new, first-of-its-kind study, led...
Kidney Failure and Its Treatment May Impact Cancer Risk
For patients with kidney failure, poor kidney function and immunosuppressant medications may increase their risk of developing different types of cancer. The findings, which are published by Yanik et al in the Journal of the American Society of Nephrology, suggest the need for persistent cancer...
New Prediction Model May Provide More Accurate Assessment of Breast Cancer Risk in Hispanic Women
A prediction model created for projecting absolute invasive breast cancer risk in Hispanic women provides a more accurate assessment of their risk of developing breast cancer compared with existing models that are based on data from non-Hispanic women, according to a new study by Banegas et al....
Investigational NAE Inhibitor Pevonedistat Shows Potential Activity in Patients With Relapsed/Refractory Lymphoma
A phase I study evaluating the safety, pharmacokinetic profile, pharmacodynamic effects, and antitumor activity of the first-in-class investigational NEDD8-activating enzyme (NAE) inhibitor pevonedistat (TAK-924/MLN4924) in patients with relapsed/refractory lymphoma or multiple myeloma has found...
Experimental Drug Shown to Prevent Neuroblastoma in Preclinical Study
Australian scientists have identified a critical molecular “feedback loop” that helps initiate and drive neuroblastoma, a cancer of the nervous system in children that is triggered in embryonal nerve cells. This feedback loop massively accelerates cancer development. The research team...
Increasing Use of Preoperative Breast MRI Linked to Increased Postdiagnostic Imaging and Biopsy, Mastectomy, and Surgery Delay
In a Canadian population-based study reported in JAMA Oncology, Arnaout et al found that breast magnetic resonance imaging (MRI) is increasingly used in preoperative evaluation of women with breast cancer and that its use is associated with increased likelihood of confirmatory breast imaging,...
ABC3: Patients Speak Out Against 'Damaging Messages' About Metastatic Breast Cancer, Call for Inclusion in Discussion About Treatment Costs
Organizations that issue “damaging messages” about advanced breast cancer need to be identified and educated to change the way they talk about the disease, a patient told the Advanced Breast Cancer Third International Consensus Conference in Lisbon, Portugal, on November 5, 2015. In...
Study Shows Wide Variation in Costs to Treat Low-Risk Prostate Cancer
University of California, Los Angeles (UCLA) researchers have described costs across the entire care process for low-risk prostate cancer—from the time a patient checks in for his first appointment to his post-treatment follow-up testing—using time-driven activity-based costing. For the ...
Only 1 in 5 U.S. Patients With Pancreatic Cancer Gets Key Blood Test at Diagnosis
Only 1 in 5 patients with pancreatic cancer in the United States receives a widely available, inexpensive blood test at diagnosis that can help predict relative outcome (compared to others with the same disease stage) and guide treatment accordingly, a Mayo Clinic study showed. People who test...
Stool DNA Test Accurate in Screening for Colorectal Cancer in Alaska Native People
Cologuard stool DNA testing for colorectal cancer was found to be an accurate noninvasive screening option for Alaska Native people, a population with one of the world's highest rates of colorectal cancer, concluded researchers from the Alaska Native Tribal Health Consortium and Mayo Clinic. The...
Study Identifies Splicing Alterations That Enable Resistance to CD19 CAR T-Cell Immunotherapy
Although the CD19 antigen expressed on most B-cell acute lymphoblastic leukemias (ALL) can be targeted with chimeric antigen receptor–armed T cells (CART-19), relapse rates among pediatric and adult patients with the cancer remain high. In this study by Sotillo et al, the researchers...
FDA Approves Adjuvant Ipilimumab to Reduce the Risk of Melanoma Returning After Surgery
The U.S. Food and Drug Administration has expanded the approved use of ipilimumab (Yervoy) to include a new use as adjuvant therapy for patients who have cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm and have undergone complete resection, including total...
Newly Discovered Tumor-Suppressor Gene Affects Melanoma Survival
Of the hundreds of genes that can be mutated in a single case of melanoma, only a handful may be true drivers of cancer. A new study published by Arafeh et al in Nature Genetics, a Weizmann Institute of Science team has revealed one of the drivers of a particularly deadly subset of melanomas that...
ASCO Calls for Comprehensive Payment Reform to Address Issue of Site Neutrality
ASCO has called for comprehensive physician payment reform to support the full scope of services required by patients with cancer, rather than jeopardizing patient outcomes by reducing the available resources in a particular cancer care setting in an effort to achieve "site neutrality" in...
ASTRO 2015: Genomic Classifier Appears to Predict Metastasis in Patients With Prostate Cancer Following Prostatectomy
For men with prostate cancer who have had a prostatectomy and salvage radiation therapy, analyzing their tumor genome provides clues as to whether their cancer will metastasize, thereby enabling clinicians to better personalize treatment options, according to research presented by Den et al...
ASTRO 2015: Involved-Field Irradiation for Locally Advanced Esophageal Cancer Reduces Toxicity Without Increasing Locoregional Lymph Node Recurrence
For patients with locally advanced esophageal cancer that has spread to the lymph nodes, radiation therapy that targets only the involved lymph node regions results in less toxicity without causing a statistically significant difference in locoregional lymph node recurrence, distant failure, and...
NCCN Unveils Evidence Blocks for CML and Multiple Myeloma
The National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 26 of the world's leading cancer centers, has unveiled its new value initiative—the NCCN Evidence Blocks, published within new versions of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for...
American Cancer Society Updates Its Breast Cancer Screening Guidelines for Average-Risk Women
After commissioning a systematic evidence review of the breast cancer screening literature to inform an update of its 2003 breast cancer screening interval guideline, the American Cancer Society (ACS) released new guidelines for women at average risk of breast cancer. The recommendations include...
Researchers Link Immunosuppressive Mycophenolate Mofetil to Increased Risk of Central Nervous System Lymphoma
A study led by Johns Hopkins researchers has linked the immunosuppressive drug mycophenolate mofetil to an increased risk of central nervous system lymphoma in solid organ transplant patients. But the same study also found that another class of immunosuppressive drugs, calcineurin inhibitors, given ...
Study Finds Use of Accelerated Partial-Breast Irradiation Has Stagnated
Accelerated partial-breast irradiation was designed to be a faster, more convenient, and potentially safer way for many women with breast cancer to reduce their mortality risk and help keep their cancer from returning after surgery. But a new study shows that despite the availability of accelerated ...
A Tolerant Immune System May Increase Cancer Risk
For a malignant tumor to form, cancer cells must evade the immune system's attack. Numerous studies have already shown that cancer spreads particularly aggressively if there is an unfavorable balance between suppressing and active immune cells in the tumor microenvironment. “But we didn't...
FDA Approves Use of Nivolumab in Advanced Nonsquamous Lung Cancer
The U.S. Food and Drug Administration (FDA) today approved nivolumab (Opdivo) to treat patients with metastatic nonsquamous non–small cell lung cancer (NSCLC) whose disease progressed during or after platinum-based chemotherapy. Nivolumab is a monoclonal antibody that that blocks the...
Many Patients Do Not Accurately Recall Important Colonoscopy Details as Time Lapses
As time lapses, many patients who have undergone a colonoscopy become less and less likely to recall when and where they last had the procedure performed, who the doctor was who performed it, whether polyps were found, and, if so, the number and size of those polyps, according to new study results...
Palliative Care 2015: Collaboration Between Radiation Oncologists and Palliative Care Specialists Improves Care for Patients With Advanced Cancer
An innovative service model that partners radiation oncology with palliative care leads to better results for patients, according to a new analysis. The model of care, established at Mount Sinai Medical Center, is one of only a handful in the country. The study (Abstract 110) will be presented at...
FDA Approves Expanded Indication for Medical Device to Treat Newly Diagnosed Glioblastoma Multiforme
The U.S. Food and Drug Administration (FDA) today approved an expanded indication for the Optune tumor treating fields device to treat patients with newly diagnosed glioblastoma multiforme. It is given along with the chemotherapy drug temozolomide following standard treatments that include...
ECC 2015: Combination of Dabrafenib and Trametinib Superior to Vemurafenib Alone in Advanced Melanoma: Results of the COMBI-v Trial
The latest results from a trial of a combination of two targeted therapies (dabrafenib [Tafinlar] and trametinib [Mekinist]) to treat advanced melanoma have shown that patients are living significantly longer on the combined therapy than patients treated with vemurafenib (Zelboraf) alone. Caroline...
ECC 2015: Lung and Gastrointestinal Neuroendocrine Tumors and Results From the RADIANT-4 Trial
An international team of researchers has shown that the use of the mTOR inhibitor everolimus can delay tumor growth among both gastrointestinal and lung neuroendocrine tumors. This is particularly important for patients with lung tumors, the researchers say, because there is currently no approved...
ECC 2015: Advanced Gastrointestinal Neuroendocrine Tumors and Results From the NETTER-1 Trial
Results from a multicenter randomized international trial of an innovative treatment show a marked improvement in the length of time patients with midgut neuroendocrine tumors experience progression-free survival, researchers reported at the 2015 European Cancer Congressin Vienna, Austria, on...
Brentuximab Vedotin Effective, Safe in Elderly Hodgkin Lymphoma Patients Who Cannot Tolerate Standard Chemotherapy
A study published by Forero-Torres et al in Blood reported that brentuximab vedotin (Adcetris) is an effective and safe first course of treatment for older patients with Hodgkin lymphoma who are unfit for chemotherapy. Ineligibility for Chemotherapy Although standard chemotherapy can...
ECC 2015: First Targeted Treatment for Small Cell Lung Cancer Shows Promise
Small cell lung cancer (SCLC) is an aggressive disease that is difficult to treat and is frequently diagnosed only when it has metastasized. Five-year survival rates in SCLC, which accounts for about 14% of all lung cancers, are very low, at only 6%. Researchers presented novel findings (Abstract...
ECC 2015: Living Conditions and Gender Appear to Affect Incidence of Hodgkin Lymphoma
Living in overcrowded conditions appears to protect children and young adults against developing a particular type of Hodgkin lymphoma. This protective effect seems to suggest that infections earlier in life may stimulate the immune system to deal with future infections and cancerous cells more...
ECC 2015: Over Three-Quarters of People With Cancer Worldwide Have No Access to Safe Surgery
Over 80% of the 15 million people diagnosed with cancer worldwide in 2015 will need surgery, but less than one-quarter of them will have access to proper, safe, affordable surgical care when they need it, according to a major new Commission examining the state of global cancer surgery. The...
ECC 2015: Childhood Cancers in Europe: Progress Has Been Made, but Much Still to Do
Each year in Europe, 6,000 young people die from cancer, and two-thirds of those who survive suffer from treatment-related side effects. Although there has been considerable progress in the treatment of childhood cancers over the past few decades, and cancer in childhood is rare, these are major...
ECC 2015: EUROCARE Results Show Large Variations in Survival Among European Countries
Comparisons of cancer patients’ survival and care in Europe up to 2007 showed that although more patients are surviving for at least 5 years after diagnosis, there are large variations among countries, which are particularly significant in cancers of the blood. Milena Sant, MD, from the...
ECC 2015: Study Finds Significant Genetic Differences Between Breast Cancers That Relapse and Those That Do Not
Although most patients with breast cancer are cured after treatment, in about one in five patients, the cancer will recur, returning either to the same place as the original tumor or metastasizing to other parts of the body. Now, researchers have taken an important step toward understanding why...
Study Finds Improving Cervical Cancer Screening Practice May Generate Health Gains With Nominal Increases in Cost
Cytology-based screening has led to substantial declines in cervical cancer incidence and mortality since it was introduced in the 1940s. A population-based, cost-effective analysis investigating the benefits, costs, and cost-effectiveness of current cervical cancer screening practice, however, has ...
Unprecedented Number of Mutations Identified in Rare Melanoma
A rare form of skin cancer known as desmoplasmic melanoma may possess the highest burden of gene mutations of any cancer, suggesting that immunotherapy may be a promising approach for treatment, according to an international team led by University of California San Francisco (UCSF) scientists. One...
Preclinical Study Shows Starving Cancer Cells of Cholesterol May Inhibit Tumor Growth and Improve Drug Sensitivity
Drugs that target key proteins involved in cholesterol metabolism could represent a promising new treatment strategy for a broad range of cancers, according to research by Fox Chase Cancer Center investigators. The study, published by Gabitova et al in Cell Reports, reveals that deficiency in the...
Antifungal Agent Increases Risk of Cutaneous Squamous Cell Carcinoma in Some Lung Transplant Recipients
Voriconazole, commonly used to prevent and treat fungal infections in lung transplant recipients, significantly increases the risk for cutaneous squamous cell carcinoma in this population, according to a new study by University of California San Francisco researchers. The team recommends physicians ...
Pancreatic Cancer Action Network and AACR Invite Applications for 2016 Research Grants
The American Association for Cancer Research (AACR) and the Pancreatic Cancer Action Network announced the opening of the 2016 Research Grants Program to support early-career investigators to focus on pancreatic cancer. Two grant mechanisms, the Pathway to Leadership Grant and the Career...
Pembrolizumab Treatment May Cause Immune Cells to Express Markers of Reinvigoration
Treating patients with metastatic melanoma with the immunotherapy drug pembrolizumab (Keytruda) caused immune cells called CD8-positive T cells in the patient’s blood to express markers of reinvigoration, according to data being presented at the CRI-CIMT-EATI-AACR International Cancer...
Preclinical Study Shows Small-Protein Immunotherapeutic May Have More Antitumor Activity Than Conventional Antibodies
An engineered high-affinity programmed cell death protein 1 (PD-1) small protein that can bind to PD-L1 (PD-1 ligand) on tumors was found to be a more effective anticancer immunotherapeutic than conventional anti–PD-L1 antibodies, and this small protein was more effective in synergizing with...
Frequency of Certain Immune Cells in Blood May Predict Response to Pembrolizumab in Metastatic Melanoma
Among patients with metastatic melanoma treated with the immunotherapy drug pembrolizumab (Keytruda), those whose cancer responded to the treatment had a higher frequency of T cells that were positive for the proteins CD8, PD-1, and Bim (CD8+PD-1+Bim+ T cells) in blood samples taken immediately...
Long-Term Infusion of Immunotherapy May Reduce Pain in Children With High-Risk Neuroblastoma
Changing the infusion delivery method of the monoclonal antibody ch14.18/CHO (dinutuximab-beta, the European counterpart of dinutuximab [Unituxin]) in combination with interleukin-2 and oral 13-cis-retinoic acid from short-term infusion to long-term infusion in the treatment of children with...
Brazilian Wasp Venom May Be Active Against Cancer Cells
The social wasp Polybia paulista protects itself against predators by producing venom known to contain a powerful cancer-fighting ingredient. A Biophysical Journal study published by Bueno Leite et al revealed how the venom's toxin—called MP1 (Polybia-MP1)—may selectively kill cancer...
